EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 107 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma MOST POPULAR 2020 Cancer Incidence and Mortality in EU-27 Countries July 24, 2020 Cancer in My Community: Caring for Children With Cancer in Paraguay June 8, 2023 Talking With Your Doctor About Negative Emotions During Cancer November 3, 2020 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... June 6, 2022 Load more HOT NEWS Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients... Medicare Open Enrollment is Here! Making Important Decisions During Cancer: A Survivor’s Story ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ
